AstraZeneca buys biotech firm
Article Abstract:
AstraZeneca PLC of the United Kingdom has acquired its partner Cambridge Antibody Technology Group PLC also of the United Kingdom. Share price offer is 13.20 Pounds ($25.01) that values the biotechnology company at approximately 702 million Pounds. The acquisition is valued at 567 million Pounds excluding the AstraZeneca PLC stake of 19.2 percent.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
ICOS accepts Lilly's sweetened takeover offer
Article Abstract:
Eli Lilly and Co. of the United State is to acquire ICOS Corp. also of the United States for $2.3 billion or $34 per share. ICOS Corp. and Eli Lilly and Co. through a joint venture are marketing the erectile-dysfunction drug Cialis. Projected sales for the drug are $965 million in 2006.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Teva Agrees to buy CoGenesys, gaining foothold in biologics
Article Abstract:
Israel's Teva Pharmaceutical Industries Ltd. has purchased US-based CoGenesys Inc., a spinoff of biotechnology firm Human Genome Sciences Inc. The $400 mil cash deal gives Teva, which focuses on generic drug development, an entry into the biologic therapies market.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2008
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: AstraZeneca hopes purchase breaks new-product slump: MedImmune offers access to vaccines, biological drugs. Two deals for Europe's drug makers
- Abstracts: Telefonica's profit jumps 40%. Telefonica profit jumps 39% on gain from Endemol sale. Telefonica shows 1.1% profit gain
- Abstracts: Gazprom, Rosneft each pursue deal to acquire Sibneft. Rosneft profit falls 55%
- Abstracts: LSE rebuffs offer by Nasdaq valuing firm at $5.1 billion. Euronext creator reaches for new deal. Euronext, NYSE take merger talk to the next level